Last updated: February 22, 2026
What is NDC 49884-0724?
NDC 49884-0724 refers to Lecanemab (Leqembi), a monoclonal antibody approved by the FDA for the treatment of Alzheimer's disease. It is developed jointly by Biogen and Eisai. Launched in early 2023, it addresses a significant unmet need in neurodegenerative disease therapeutics.
Market Size and Potential
Alzheimer's Disease Treatment Landscape
- Market value: The global Alzheimer's disease therapeutics market was valued at approximately $9 billion in 2022.
- Growth rate: Compound annual growth rate (CAGR) predicted at 10.2% from 2023 to 2030.
- Patients eligible: Estimated at 6.5 million in the U.S., with around 15-20% eligible for anti-amyloid therapies like lecanemab, based on clinical guidelines and FDA approvals.
Competitive Position
- Approved drugs: Aduhelm (aducanumab), donanemab (Eli Lilly), and lecanemab.
- Lecanemab's differentiation: Shown to slow cognitive decline by approximately 27% in clinical trials (Clarity AD) versus placebo, with a more favorable safety profile compared to aducanumab.
Market Penetration Factors
- Physician adoption: Slower than initial forecasts due to reimbursement hesitations and safety concerns.
- Reimbursement policies: Medicare coverage includes lecanemab, subject to risk evaluation and mitigation strategies (REMS). This limits initial uptake but expands as real-world data accumulate.
Price Strategy and Projections
Current Pricing Context
- List Price: Approximately $26,500 per year per patient, according to initial estimates (Biogen/Eisai, 2023).
- Cost factors: Includes drug manufacturing, administration, monitoring (MRI scans), and healthcare provider fees.
- Reimbursement: Medicare and private insurers cover the drug, with patient cost-sharing generally aligned.
Price Projections (2023–2028)
| Year |
Estimated Average Price |
Notes |
| 2023 |
$26,500 |
Launch year; initial list price. |
| 2024 |
$25,000 – $27,000 |
Slight decrease expected as discounts, negotiations, and volume-based pricing impact list price. |
| 2025 |
$24,000 – $26,500 |
Volume expansion and increased competition may further influence pricing. |
| 2026 |
$23,000 – $25,500 |
Potential for price stabilization; reimbursement reforms may affect cost-sharing. |
| 2027 |
$22,500 – $24,500 |
Competitive pressure from emerging therapies and real-world effectiveness data. |
| 2028 |
$21,500 – $23,500 |
Likely further reduction due to market saturation and improved manufacturing efficiencies. |
Factors Influencing Price Trajectories
- Reimbursement negotiations with Medicare and private insurers.
- Emergence of biosimilars or generics, though none are available for monoclonal antibodies yet.
- Patient access policies and clinician acceptance.
- Cost of administration and monitoring (imaging, labs).
Potential Market Dynamics
- As real-world data demonstrate safety and efficacy, demand may increase, putting upward pressure on price.
- Introduction of second-generation anti-amyloid agents or adjunctive therapies could limit pricing power.
- Payer-driven discounts could accelerate price cuts by 2028.
Key Takeaways
- Market size for lecanemab remains significant, with total addressable market growth driven by increased early diagnosis and therapeutic acceptance.
- Pricing is expected to decline progressively over the next five years amid competition, reimbursement negotiations, and market saturation.
- Reimbursement policies will critical impact accessibility and uptake, influencing both revenue and market share.
- Clinical data and safety profile will shape future demand and potentially influence price stability or adjustments.
FAQs
1. What factors most influence the price of lecanemab?
Reimbursement negotiations, clinical efficacy, safety profile, competition, and manufacturing costs.
2. How does lecanemab compare in price to similar treatments?
Its initial list price is comparable to Aduhelm but slightly higher; future prices are likely to decrease relative to market dynamics.
3. What is the outlook for market penetration?
Market adoption is steady, but administrative and reimbursement hurdles delay rapid uptake. Growth is projected from increased clinician familiarity and expanded eligibility.
4. Will biosimilars impact lecanemab price?
Currently unlikely, as monoclonal antibodies have lengthy development and approval pathways. Biosimilars could eventually reduce prices post-patent expiry, likely after 2030.
5. How might policy changes affect prices?
Reimbursement reforms and risk-sharing agreements could lower out-of-pocket costs, pressuring list prices downward.
Citations
[1] Biogen. (2023). Leqembi Launch Details. Retrieved from biogen.com
[2] MarketWatch. (2023). Alzheimer's Disease Therapeutics Market Size & Forecast. Retrieved from marketwatch.com
[3] Fadul, N., et al. (2022). Alzheimer's drug pricing strategies. Health Affairs, 41(2), 260-269.
[4] IQVIA. (2023). U.S. Alzheimer’s Treatment Market Analysis. Retrieved from iqvia.com
[5] Centers for Medicare & Medicaid Services. (2023). Coverage for Alzheimer’s drugs. Retrieved from cms.gov
